Staff Profile

Qualifications

B.Sc. Hons           Pure Science, University of Glasgow

D.Phil.                   Biochemistry, University of Oxford

Scholarship and Fellowship Awards:

MRC Training Scholarship.

Royal Society Research Fellowship.

EMBO Long Term Travelling Fellowship.

Royal Society University Research Fellowship.

Previous Substantive Appointments:

Chargée de Recherche, INSERM U148, Montpellier, France.

Lecturer, Department of Pathology, University of Newcastle..

Senior Lecturer, Department of Pathology, University of Newcastle.

Memberships

Breast Cancer Research Group

British Association for Cancer Research

European Association for Cancer Research

Oesophagogastric cancer group

Overall Research Interests

The molecular basis of breast, gastric and oesophageal cancer development

Molecular diagnostics for improved treatment individualisation in breast, gastric and oesophageal cancer patients

Development and pre-clinical assessment of novel therapies for breast, gastric and oesophageal cancer patients

 We work on the dependence and response of adult adenocarcinomas, majorly of the stomach, oesophagus and breast, and gynaecological cancers, to steroidal and protein hormones. We investigate how these dependencies may be developed therapeutically, particularly by inhibition of receptors and protein kinases. We are interested in how malignant cells evolve and adapt to invade effectively, and to acquire therapeutic resistance.  We are interested in the unexploited prognostic, predictive and pharmacodynamic potential of biomarker measurements on circulating tumour cells and other disseminated malignant cells.

 Theme 1: Dependence and response of malignant of cells to endocrine stimuli.

Our research aims to understand in what way and how malignant cells respond to external growth factors in particular oestrogens, insulin-like growth factors, epidermal growth factors and trefoil factors. Future work will be informed by recent whole genomic analyses that demonstrate that individual cancers are driven by specific pathways.  It is important to validate these findings especially in oesophageal and gastric adenocarcinoma for which there are scarce effective therapeutic options.  Ex vivo analyses on disseminated tumour cells isolated directly from patients will contribute to validation of novel targets. The goal is to provide preclinical and translational evidence for clinical trials in oesophagogastric cancers.

Theme 2: Validation of predictive and pharmacodynamic biomarkers

The heterogeneity of cancer and different responses of individual tumours to cytotoxic and biological drugs necessitates effective patient stratification if response rates are to increase and novel therapies are to be adopted. The value of predictive biomarkers of response to targeted therapies is proven in breast cancer but we have demonstrated that it could be improved. Our work combines preclinical identification of potential predictive biomarkers with translation validation. The potential of biomarker measurements in disseminated disease for initial treatment stratification and for therapeutic monitoring is a particular future focus.

Theme 3: Evolution of malignant disease

We are interested in how malignant cells disseminate in individual patients, in how cells in the primary tumour evolve, and how they differ from those in the circulation, bone marrow or secondary deposits. These studies will further understanding of the disease and have the potential to improve pre-operative staging of oesophagogastric cancer patients.  Analyses on sequential samples from patients with advanced disease will increase understanding about this evolution and determine if monitoring might inform patient management. We should like to develop our work on disseminated cells isolated from patients who acquire resistance to novel therapies. The large number of circulating tumour cells identified in some oesophagogastric cancer patients suggests that we should be able to isolate the cells for individual genomic analyses and potentially to study the cells in culture.

Postgraduate Supervision

Masters students registered of MRes Programmes or MSc Medical Sciences Programmes

Intercalated medical students

PhD students

Clinical Research Fellows

Funding

Breast Cancer Campaign

Cancer Research UK (CR-UK)

JGW Patterson Foundation

Medical Research Council (MRC)

Newcastle Healthcare Charity

Northern Oesophagogastric Cancer Fund

Wellbeing of Women

Postgraduate Teaching

Degree Programme Director, MSc Medical Sciences Programme 5814F

Programme Leader, MRes Cancer Programme 4816F

Chairman Board of Examiners, MSc Medical Sciences Programme 5814F

Module Leader, MMS8101 Cancer Studies Module

Module Leader, MMS8107 Medical Research Practice Module

Module Leader, MMS8199 Dissertation Module

Module Leader, MMB8007 Cancer Studies Module

Undergraduate Teaching

Lecturer, BMS3010 Genetics of Common Disease

Supervisor, BSc Biomedical Sciences Programme B940

Supervisor, BSc Physiological Sciences Programme B100

Supervisor, BSc Pharmacology Programme B210

Supervisor, MSci Biomedical Sciences Programme B900

• Dent BM, Ogle LF, O'Donnell RL, Hayes N, Mallick U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FEB, Jamieson D. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer 2016, 138(1), 206-216.
• Saisana M, Griffin SM, May FEB. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget 2016, 7(34), 54445-54462.
• Luey BC, May FEB. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinease/Akt pathway. Molecular Cancer 2016, 15(8).
• Wade MA, Sunter NJ, Fordham SE, Long A, Masic D, Russell J, Harrison CJ, Rand V, Elstob C, Bown N, Rowe D, Lowe C, Cuthbert G, Bennett S, Crosier S, Bacon CM, Onel K, Scott K, Scott D, Travis LB, May FEB, Allan JM. c-MYC is a radiosensitive locus in human breast cells. Oncogene 2015, 34, 4985-4994.
• Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FEB, Allan JM, Pollard JR, Curtin NJ. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 2015, 6(32), 32396-32409.
• May FEB, Westley BR. TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocrine-Related Cancer 2015, 22, 465-479.
• Dunne C, Kilcoyne M, Robbe-Masselot C, Kane L, Clare S, May FEB, Clyne M. The role of TFF1 in promoting colonization of the Gastric Mucosa by Helicobacter pylori. In: Irish Society of Gastroenterology – Winter Meeting. 2015, Dublin, Ireland: Spinger London.
• Dent B, O'Donnell RL, Ogle LF, Rourke ED, Ramesh HP, Moat M, Hayes N, Mallick UK, May FE, Reeves HL, Curtain NJ, Edmondson RJ, Boddy AV, Plummer R, Jamieson D. Detection and characterization of circulating tumor cells by imaging flow cytometry. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
• May FEB. Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer. Cancer Management and Research 2014, 6, 225-252.
• Westley RL, May FEB. A Twenty-First Century Cancer Epidemic Caused by Obesity: The Involvement of Insulin, Diabetes, and Insulin-Like Growth Factors. International Journal of Endocrinology 2013, 2013, 632461.
• Axon A, May FEB, Gaughan LE, Williams FM, Blain PG, Wright MC. Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology 2012, 298(1-3), 40-51.
• Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB. TFF3 Is a Normal Breast Epithelial Protein and Is Associated with Differentiated Phenotype in Early Breast Cancer but Predisposes to Invasion and Metastasis in Advanced Disease. American Journal of Pathology 2012, 180(3), 904-916.
• Dolan B, Naughton J, Tegtmeyer N, May FEB, Clyne M. The Interaction of Helicobacter pylori with the Adherent Mucus Gel Layer Secreted by Polarized HT29-MTX-E12 Cells. PLoS One 2012, 7(10), e47300.
• May FEB. The potential of trefoil proteins as biomarkers in human cancer. Biomarkers in Medicine 2012, 6(3), 301-304.
• Davison Z, de Blacquière GE, Westley BR, May FEB. Insulin-like Growth Factor-Dependent Proliferation and Survival of Triple-Negative Breast Cancer Cells: Implications for Therapy. Neoplasia 2011, 13(6), 504-515.
• Arumugam T, Brandt W, Ramachandran V, Moore TT, Wang HM, May FE, Westley BR, Hwang RF, Logsdon CD. Trefoil Factor 1 Stimulates Both Pancreatic Cancer and Stellate Cells and Increases Metastasis. Pancreas 2011, 40(6), 815-822.
• Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May FEB, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics 2011, 21(12), 808-819.
• Wright PK, May FEB, Darby S, Saif R, Lennard TWJ, Westley BR. Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. International Journal of Clinical and Experimental Pathology 2009, 2(5), 463-475.
• de Blaquière GE, May FEB, Westley BR. Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocrine-Related Cancer 2009, 16(2), 635-647.
• May FEB, Griffin SM, Westley BR. The trefoil factor interacting protein TFIZ1 binds the trefoil protein TFF1 preferentially in normal gastric mucosal cells but the co-expression of these proteins is deregulated in gastric cancer. International Journal of Biochemistry & Cell Biology 2009, 41(3), 632-640.
• Reeves EP, Ali T, Leonard P, Hearty S, O'Kennedy R, May FEB, Westley BR, Josenhans C, Rust M, Suerbaum S, Smith A, Drumm B, Clyne M. Helicobacter pylori Lipopolysaccharide Interacts With TFF1 in a pH-Dependent Manner. Gastroenterology 2008, 135(6), 2043-2054.
• Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FEB, Gao J, Meitner PA, Tavares R, Resnick MB. Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: Influence of tumor histology and relationship to prognosis. Clinical Cancer Research 2008, 14(13), 4161-4167.
• Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, May FEB, Westley BR, Tepsiri N, Paupairoj A, Chau-in S. Increased TFF1 trefoil protein expression in Opisthorchis viverrini-associated cholangiocarcinoma is important for invasive promotion. Hepatology Research 2007, 37(4), 295-304.
• Johns C, Newton JL, Westley BR, May FEB. Human pancreatic polypeptide has a marked diurnal rhythm that is affected by ageing and is associated with the gastric TFF2 circadian rhythm. Peptides 2006, 27(6), 1341-1348.
• Westley BR, May FEB. Identification of steroid hormone-regulated genes in breast cancer. In: Brooks SA; Harris A, ed. Breast Cancer Research Protocols. Humana Press, 2006, pp.363-388.
• Chutipongtanate S, Nakagawa Y, Sritippayawan S, Pittayamateekul J, Parichatikanond P, Westley B, May F, Malasit P, Thongboonkerd V. Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor. Journal of Clinical Investigation 2005, 115(12), 3613-3622.
• Westley BR, Griffin S, May FEB. Interaction between TFF1, a gastric tumor suppressor trefoil protein, and TFIZ1, a brichos domain-containing protein with homology to SP-C. Biochemistry 2005, 44(22), 7967-7975.
• Thim L, May FEB. Structure of mammalian trefoil factors and functional insights. Cellular and Molecular Life Sciences 2005, 62(24), 2956-2973.
• Johns CE, Newton JL, Westley BR, May FEB. The diurnal rhythm of the cytoprotective human trefoil protein TFF2 is reduced by factors associated with gastric mucosal damage: Ageing, Helicobacter pylori Infection, and sleep deprivation. American Journal of Gastroenterology 2005, 100(7), 1491-1497.
• Lafontaine PO, Arnal M, Buron N, Solary E, Bron AM, Westley BR, May FEB, Bara J, Gespach C, Creuzot-Garcher C. Trefoil factor family mRNA and protein expression in pterygium. International Journal of Oncology 2005, 27(4), 997-1003.
• Pu M, May FEB, Playford R, Ruchaud-Sparagano M, Westley BR. Development of a two-site ELISA assay for the dimeric form of human TFF1. Peptides 2004, 25(5), 731-736.
• May FEB, Semple J, Prest S, Westley BR. Expression and motogenic activity of TFF2 in human breast cancer cells. Peptides 2004, 25(5), 865-872.
• Clyne M, Dillon P, Daly S, O'Kennedy R, May F, Westley B, Drumm B. Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(19), 7409-7414.
• FitzGerald A, Pu M, Marchbank T, Westley BR, May FEB, Boyle J, Yadollahi-Farsani M, Ghosh S, Playford R. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 2004, 25(5), 793-801.
• Newton J, Johns CE, May FEB. The ageing bowel and intolerance to aspirin. Alimentary Pharmacology and Therapeutics 2004, 19(1), 39-45.
• Ruchaud-Sparagano M, Westley BR, May FEB. The trefoil protein TFF1 is bound to MUC5AC in human gastric mucosa. Cellular and Molecular Life Sciences 2004, 61(15), 1946-1954.
• Carrasco R, Pera M, May F, Westley B, Martinez A, Morales L. Trefoil factor family peptide 3 prevents the development and promotes healing of ischemia-reperfusion injury in weanling rats. Journal of Pediatric Surgery 2004, 39(11), 1693-1700.
• Soriano-Izquierdo A, Gironella M, Massaguer A, May FEB, Salas A, Sans M, Poulsom R, Thim L, Piqué J, Panés J. Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. Journal of Leukocyte Biology 2004, 75(2), 214-223.
• Johns CE, Newton JL, Westley BR, May FEB. Expression of the cytoprotective trefoil protein TFF2 in human gastric and duodenal biopsies. In: Annual meeting of the British-Society-of-Gastroenterology. 2003, Birmingham: Gut.
• Rodrigues S, Attoub S, Nguyen Q, Bruyneel E, Rodrigue C, Westley B, May F, Thim L, Mareel M, Emami S, Gespach C. Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. Oncogene 2003, 22(29), 4488-4497.
• Muskett F, May FEB, Westley BR, Feeney J. Solution Structure of the Disulfide-Linked Dimer of Human Intestinal Trefoil Factor (TFF3): The Intermolecular Orientation and Interactions Are Markedly Different from Those of Other Dimeric Trefoil Proteins. Biochemistry 2003, 42(51), 15139-15147.
• May FEB, Church S, Major S, Westley BR. The closely related estrogen-regulated trefoil proteins TFF1 and TFF3 have markedly different hydrodynamic properties, overall charge, and distribution of surface charge. Biochemistry 2003, 42(27), 8250-8259.
• Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen Q, Bruyneel E, Westley BR, May FEB, Thim L, Mareel M, Gespach C, Emami S. Trefoil peptides as proangiogenic factors in vivo and in vitro: Implication of cyclooxygenase-2 and EGF receptor signaling. The FASEB Journal 2003, 17(1), 7-16.
• Prest SJ, May FEB, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. The FASEB Journal 2002, 16(2), 592-+.
• Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. The FASEB Journal 2001, 15(9), 1517-1528.
• Semple J, Newton JL, Westley BR, May FEB. Dramatic diurnal variation in the concentration of the human trefoil peptide TFF2 in gastric juice. Gut 2001, 48(5), 648-655.
• Crosier M, Scott D, Wilson RG, Griffiths CDM, May FEB, Westley BR. High expression of the trefoil protein TFF1 in interval breast cancers. American Journal of Pathology 2001, 159(1), 215-221.
• Emami S, Le Floch N, Bruyneel E, Thim L, May FEB, Westley BR, Rio MC, Mareel M, Gespach C. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. The FASEB Journal 2001, 15(2), 351-361.
• Williams M, Westley B, May F, Feeney J. The solution structure of the disulphide-linked homodimer of the human trefoil protein TFF1. FEBS Letters 2001, 493(2-3), 70-74.
• Molloy CA, May FEB, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. Journal of Biological Chemistry 2000, 275(17), 12565-12571.
• Newton JL, Allen A, Westley BR, May FEB. The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach. Gut 2000, 46(3), 312-320.
• May FEB, Semple J, Newton JL, Westley BR. The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach. Gut 2000, 46(4), 454-459.
• Crosier M, Scott D, Wilson RG, Griffiths CDM, May FEB, Westley BR. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clinical Cancer Research 1999, 5(10), 2682-2688.
• Andersson ML, Lindeskog M, Medstrand P, Westley BR, May FEB, Blomberg J. Diversity of human endogenous retrovirus class II-like sequences. Journal of General Virology 1999, 80(1), 255-260.
• Westley BR, May FEB. Prognostic value of cathepsin D in breast cancer. British Journal of Cancer 1999, 79(2), 189-190.
• Donaghue C, Westley BR, May FEB. Selective promoter usage of the human estrogen receptor-alpha gene and its regulation by estrogen. Molecular Endocrinology 1999, 13(11), 1934-1950.
• Calnan DP, Westley BR, May FEB, Floyd DN, Marchbank T, Playford RJ. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. Journal of Pathology 1999, 188(3), 312-317.
• Marchbank T, Westley BR, May FEB, Calnan D, Playford R. Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. Journal of Pathology 1998, 185(2), 153-158.
• Westley BR, Clayton SJ, Daws MR, Molloy CA, May FEB. Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. In: Annual Symposium on Mammary Development and Cancer, as Part of the 658th Meeting of the Biochemical-Society. 1998.
• May FEB, Westley BR. Close physical linkage of the genes encoding the pNR-2/pS2 protein and human spasmolytic protein (hSP). Human Genetics 1997, 99(3), 303-307.
• May FEB, Westley BR. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. Journal of Pathology 1997, 182(4), 404-413.
• Polshakov V, Williams M, Gargaro A, Frenkiel T, Westley BR, Chadwick M, May FEB, Feeney J. High-resolution solution structure of human pNR-2/pS2: A single trefoil motif protein. Journal of Molecular Biology 1997, 267(2), 418-432.
• Chadwick MP, Westley BR, May FEB. Homodimerization and hetero-oligomerization of the single-domain trefoil protein pNR-2/pS2 through cysteine 58. Biochemical Journal 1997, 327, 117-123.
• Clayton SJ, May FEB, Westley BR. Insulin-like growth factors control the regulation of oestrogen and progesterone receptor expression by oestrogens. Molecular and Cellular Endocrinology 1997, 128(1-2), 57-68.
• May FEB, Westley BR. Trefoil proteins: Their role in normal and malignant cells. Journal of Pathology 1997, 183(1), 4-7.
• Westley BR, May FEB. Cathepsin D and breast cancer. European Journal of Cancer 1996, 32A(1), 15-24.
• Hodgson D, May FEB, Westley BR. Involvement of phenylalanine 23 in the binding of IGF-1 to the insulin and type I IGF receptor. Regulatory Peptides 1996, 66(3), 191-196.
• Daws MR, Westley BR, May FEB. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. Endocrinology 1996, 137(4), 1177-1186.
• Carr M, May FEB, Lennard TWJ, Westley BR. Determination of estrogen responsiveness of breast cancer by competitive reverse transcription polymerase chain reaction. British Journal of Cancer 1995, 72(6), 1427-1434.
• Westley BR, May FEB. Insulin like growth factors: the unrecognised oncogenes. British Journal of Cancer 1995, 72(5), 1065-1066.
• Westley BR, May FEB. In-vitro development of tamoxifen resistance. In: International Meeting on Current Topics in Breast Cancer Research. 1995, Cambridge: Endocrine - Related Cancer.
• Hodgson DR, May FEB, Westley BR. Mutations at position-11 and postition-60 of insulin like growth factor 1 reveal differences between its interactions with the type-I insulin like growth factor receptor and insulin receptor. European Journal of Biochemistry 1995, 233(1), 299-309.
• Chadwick MP, May FEB, Westley BR. Production and comparison of mature single domain trefoil peptides PNR-2/PS2 CYS(58) and PNR-2/PS2 SER(58). Biochemical Journal 1995, 308, 1001-1007.
• May FEB, Westley BR. Estrogen regulated messenger RNAs in human breast cancer cells. Biomedicine & Pharmacotherapy 1995, 49(9), 400-414.
• Stewart AJ, Piggott NH, May FEB, Westley BR. Mitogenic activity of procathepsin-D purified from conditioned medium of breast cancer cells by affinity chromatography on pepstatinyl agarose. International Journal of Cancer 1994, 57(5), 715-718.
• Westley BR, May FEB. Role of insulin like growth factors in steroid modulated proliferation. The Journal of Steroid Biochemistry and Molecular Biology 1994, 51(1-2), 1-9.
• Henry JA, Hennessy C, Levett DL, Lennard TWJ, Westley BR, May FEB. INT-2 amplification in breast cancer: association with decreased survival and relationship to amplification of C-ERBB-2 and C-MYC. International Journal of Cancer 1993, 53(5), 774-780.
• Healicon RM, Westley BR, May FEB. Isolation and characterization of an estrogen responsice breast cancer cell line, EFF-3. International Journal of Cancer 1993, 53(3), 388-394.
• May FEB, Smith DJ, Westley BR. The human cathepsin d-encoding is transcribed from an estrogen regulated and a constitutive start point. Gene 1993, 134(2), 277-282.
• Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FEB, Westley BR. Type-I IGF receptor and acquired tamoxifen resistance in estrogen responsive human breast cancer cells. European Journal of Cancer 1993, 29A(16), 2256-2264.
• Collier JD, Guo K, Mathew J, May FEB, Bennett MK, Corbett IP, Bassendine MF, Burt AD. C-erbb-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. Journal of Hepatology 1992, 14(2-3), 377-380.
• Stewart AJ, Westley BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by estrogen. British Journal of Cancer 1992, 66(4), 640-648.
• Cochrane HR, May FEB, Ashcroft T, Dark JH. Enteroviruses and idiopathic dilated cardiomyopathy. Journal of Pathology 1991, 163(2), 129-131.
• Henry JA, Bennett MK, Piggott NH, Levett DL, May FEB, Westley BR. Expresison of the PNR-2 PS2 protein in diverse human epithelial tumors. British Journal of Cancer 1991, 64(4), 677-682.
• Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ. Expression of antimetastatic gene NM23. British Journal of Cancer 1991, 63(6), 1024-1024.
• Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ. Expression of the antimetastatic gene NM23 in human breast cancer: an association with good prognosis. Journal of the National Cancer Institute 1991, 83(4), 281-285.
• Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, May FEB. PNR-2 PS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. British Journal of Cancer 1991, 63(4), 615-622.
• Henry JA, McCarthy AL, Piggot NH, Angus B, Levett D, Johnson SJ, Hennessy C, Lennard TWJ, May FEB, Westley BR. The prognostic significance of the lysosomal protease cathepsin-D in human breast cancer - an immunohistochemical study. Journal of Pathology 1991, 164(4), A359-A359.
• Piggott NH, Henry JA, May FEB, Westley BR. Antipeptide antibodies against the PNR-2-estrogen regulated protein of human breast cancer cells and detection of PNR-2 expression in norman tissue by immunohistochemistry. Journal of Pathology 1991, 163(2), 95-104.
• Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Cairns J, Harris AL, Horne CHW.
  Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study.
  . CANCER 1990, 65(2), 265-271.
• Henry JA, Nicholson S, Hennessy C, Lennard TWJ, May FEB, Westley BR. Expression of the estrogen regulated PNR-2 messenger RNA in human breast cancer: relation to estrogen receptor messenger RNA levels and response to tamoxifen therapy. British Journal of Cancer 1990, 61(1), 32-38.
• Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, Gullick WJ, Tuzi NL, May FEB, Westley BR, Horne CHW. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbb-2 oncogene protein effective for use on formalin fixed, paraffin embedded tissue. Journal of Pathology 1990, 161(1), 15-25.
• Stewart AJ, Johnson MD, May FEB, Westley BR. Role of insulin like growth factors and the type I insulin like growth factor receptor in the estrogen stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry 1990, 265(34), 21172-21178.
• Westley BR, Holzel F, May FEB. Effects of estrogen and the antioestrogens, tamoxifen and LY117018, on 4 estrogen regulated RNAs in the EFM-19 breast cancer cell line. The Journal of Steroid Biochemistry and Molecular Biology 1989, 32(3), 365-372.
• Johnson MD, Westley BR, May FEB. Estrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. British Journal of Cancer 1989, 59(5), 727-738.
• May FEB, Johnson MD, Wiseman LR, Wakeling AE, Kastner P, Westley BR. Regulation of progesterone receptor messenger RNA by estradiol and antioestrogens in breast cancer cell lines. The Journal of Steroid Biochemistry and Molecular Biology 1989, 33(6), 1035-1041.
• May FEB, Westley BR. Characterization of sequences related to the mouse mammary tumor virus that are specific to MCF-7 breast cancer cells. Cancer Research 1989, 49(14), 3879-3883.
• Wiseman LR, Wakeling AE, May FEB, Westley BR. Effects of the antiestrogen, ICI-164,384 on estrogen enduced RNAS in MCF-7 cells. The Journal of Steroid Biochemistry and Molecular Biology 1989, 33(1), 1-6.
• Westley BR, May FEB. Estrogen regulates estrogen receptor messenger RNA levels in an estrogen responsive human breast cancer cell line. Biochemical and Biophysical Research Communications 1988, 155(3), 1113-1118.
• Henry JA, May FEB, Westley BR. Expression of estrogen regulated PNR-2 messenger RNA in human breast cancer. Journal of Pathology 1988, 155(4), A349-A349.
• Franklin GC, Chretien S, Hanson IM, Rochefort H, May FEB, Westley BR. Expression of human sequences related to those of mouse mammary tumor virus. Journal of Virology 1988, 62(4), 1203-1210.
• May FEB, Westley BR. Identification and characterization of estrogen regulated RNAs in human breast cancer cells. Journal of Biological Chemistry 1988, 263(26), 12901-12908.
• Henry JA, Nicholson S, Farndon JR, Westley BR, May FEB. Measurement of estrogen receptor messenger RNA levels in human breast tumors. British Journal of Cancer 1988, 58(5), 600-605.
• May FEB, Westley BR. Effects of tamoxifen and 4-hydroxytamoxifen on the PNR-1 and PNR-2 estrogen regulated RNAs in human breast cancer cells. Journal of Biological Chemistry 1987, 262(33), 15894-15899.
• Westley BR, May FEB. Estrogen regulates cathepsin-D messenger RNA levels in edtrogen responsive human breast cancer cells. Nucleic Acids Research 1987, 15(9), 3773-3786.
• May FEB, Westley BR. Structure of a human retroviral sequence related to mouse mammary tumor virus. Journal of Virology 1986, 60(2), 743-749.
• May FEB, Westley BR. Cloning of estrogen regulated messenger RNA sequences from human breast cancer cells. Cancer Research 1986, 46(12), 6034-6040.